At a recent health-focused event in New York, Google announced the development of TxGemma, a series of open AI models aimed at enhancing drug discovery. These models will be released via the Health AI Developer Foundations program later this month. Designed to interpret both text and therapeutic structures, TxGemma can assist researchers in predicting the safety and efficacy of potential therapies. Despite the promise of AI in revolutionizing drug development, challenges remain, as evidenced by recent failures in clinical trials. Nevertheless, investor interest in AI-driven drug discovery continues to grow, with significant funding allocated to the sector.